Cardinal Health Stock Jumps on Guidance Raise. Why 2026 Will Be a Good Year. -- Barrons.com

Dow Jones01-13

By Mackenzie Tatananni

Cardinal Health stock jumped Tuesday after the pharmaceutical distributor boosted its fiscal-year outlook and pointed to continued growth in its specialty medicine business.

Presenting at the annual J.P. Morgan Healthcare Conference on Tuesday, Cardinal Health said it expects fiscal-year earnings of at least $10 a share, up from a prior range of $9.65 to $9.85. Analysts tracked by FactSet have been looking for $9.86 a share.

The company also projected over $50 billion in specialty revenue for the fiscal year, or revenue tied to higher-cost, complex medications such as biologics for rare diseases. If Cardinal Health reaches this milestone, it will represent a 16% compound annual growth rate over three years.

Shares gained 3.7% in premarket trading. Healthcare peers Elevance Health and UnitedHealth Group were flat and slightly lower, respectively. CVS Health, which uses Cardinal Health as a major pharmaceutical distributor, declined 0.3%.

Write to Mackenzie Tatananni at mackenzie.tatananni@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

 

(END) Dow Jones Newswires

January 13, 2026 08:49 ET (13:49 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment